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Hypothesis: Using previously-described dopamine receptor ligands, we can synthesize a bivalent
ligand that targets the D2-D3 heterodimer and is able to ameliorate positive as well as negative
symptoms of schizophrenia
HYPOTHESIS & RESEARCH OBJECTIVES
Design of a third generation antipsychotic for 
schizophrenia treatment
Design a bivalent 
ligand that 
specifically binds 
to the D2D3R 
Ensure that the 
ligand shows 
pharmacological 
activity in vitro 
Assess its effect on 
positive and 
negative symptoms 
on an animal model 
of schizophrenia
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SYMPTOMATOLOGY
Schizophrenia is a complex, debilitating, chronic psychiatric disorder that affects
roughly 1% of the world’s population; that is, 21 million people. Manifestations of the
disease include positive symptoms (hallucinations, delusions) and negative symptoms:
cognitive disturbances that include avolition, emotional dysregulation, apathy, lack of
initiative and motivation, anhedonia and social withdrawal; and expressive deficits which
include blunted affect and poverty of speech.
Although their clinical expression is less obvious than that of positive symptoms,
negative symptoms can significantly impact patients’ psychosocial functioning, quality
of life and long-term outcome. Amongst others, dopaminergic dysregulation seems to
be responsible for the pathophysiology of the disease. Antipsychotic medication mostly
targets dopamine D2 receptors and is able to ameliorate positive symptoms, although
they cause side effects that include hyperprolactinemia, extrapyramidal symptoms (EPS)
and severe tardive dyskinesia (TD).
Despite its societal burden, no available treatment for schizophrenia is free of side
effects or is able to successfully ameliorate positive and negative symptoms. Partial D2
agonists are believed to cause fewer EPS than total agonists. Recent research has found
D3-preferring antagonists have an effect on negative symptoms. Also, D2-D3
heteromer formation has been suggested to have pathophysiological implications and
proposed as a potential drug target.
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ANALYSIS
HEK 293T cells will be cultured in standard
conditions in DMEM + 10% FBS + antibiotics. Cells
will be transfected with the plasmid DNA containing
dopamine receptors and the chimeric AC‐V/VI by the
Polyethylenimine method.
TRANSFECTION
The ZDOCK protocol in Discovery studio 2.5 suite will be used to search the
heterodimer interface of the minimized receptor crystal structures. We will use a
computational tool designed specifically for this to calculate the preferred
spacer length for the selected interface.
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CATALEPSY
Animals will be placed with the forepaws on a high
podium. Rats will be considered cataleptic if they do
not correct their body posture within 30s.
Rats will be placed in square cages equipped with
infrared photobeams along the bottom of the cage for
an hour. Motor activity will be determined as the total
number of beam interruptions during this period.
MOTOR ACTIVITY
Acquisition trial: animals placed in the test box and
allowed to explore 2 identical objects. Retention trial:
animals placed in the test box with 1 duplicate object
from the acquisition and 1 novel object- Total object
exploration time and discrimination index will be
analysed.
NOVEL OBJECT RECOGNITION
Two unfamiliar rats will be placed in a open-field box
with black gridlines, with an unfamiliar object for a 10’
period. We will score following, investigative sniffing
behavior, avoidance, object exploration, and line
crossings.
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→ →determine in vivo binding of  [3H](+)-PHNO →demonstrate 
in vivo D2/D3 binding affinity of novel drug 
Three days after transfection, HEK293T cells will be
suspended in Tris·HCl pH 7.4 buffer with different
concentrations of [3H]raclopride with the added
presence of varying concentrations of the
unlabeled bivalent ligand. The nonspecific binding
will be determined in the presence of haloperidol.
Free and cell-bound ligand will be separated by
rapid filtration. The radioactivity counts will be
measured with a Tri-Carb 2800TR liquid scintillation
analyzer.
→ → Structure based pharmacophore → Virtual Screening
DOCKING
For all minimized ligand-receptor pairs, the ligand will be docked and its
stability will be assessed by 1 µs of unbiased molecular dynamics simulation.
DETERMINING LINKER LENGHT
PEG
DESIGN
The selected pharmacophores, a D3-prefferrng partial agonist, and a D2 partial
agonist, will be linked by PEG molecules, to avoid increases in hydrophobicity,
using Chemsketch .
Following single i.v. and p.o. 
administration of novel drug
PCP: NDMA antagonist that 
induces positive and 
negative-like symptoms
RADIOLIGAND BINDING
cAMP ACCUMULATION
24h after transfection cells will be incubated for 2h
with fresh growth medium containing [3H]adenine,
which will be replaced by medium containing
phosphodiesterase inhibitors. After, they will be
incubated with forskolin in the presence or absence
of the bivalent receptor ligand. The amount of
recovered [3H]cAMP will be determined by a two-
step column separation procedure,
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→ → BiFC assay: Are receptors dimerizing?
DISSCUSSION AND CONCLUSIONS
Available treatment for schizophrenia presents serious side effects such as extrapyramidal
symptoms and tardive dyskinesia and fails to ameliorate negative symptoms of the disease,
which have an important impact on the patient’s psychosocial and clinical long-term
outcome.
1. Further research is necessary to
find an effective treatment for all
schizophrenia symptomatology.
2. Computational tools are useful
for studying protein-protein
interactions and drug design.
3. In vitro techniques allow us to
study novel drug´s pharmacology.
4. Rats are a good model in which
to study complex processes such as
pharmacokinetics and behavioral
changes.
